Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XTR006 (also known as MK-6240) is an 18F-labeled small molecule radiopharmaceutical being developed by Sinotau Pharmaceutical Group (in-licensed from Cerveau Technologies) as a positron emission tomography (PET) imaging agent. It specifically targets aggregated microtubule-associated protein tau (neurofibrillary tangles), which is a hallmark pathology of Alzheimer's disease and other tauopathies. By binding to these proteins with high affinity and selectivity, XTR006 allows for the non-invasive visualization and quantification of tau burden in the brain. This diagnostic tool is intended to support the identification and monitoring of mild cognitive impairment (MCI) due to Alzheimer's disease and Alzheimer's disease dementia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MK-6240.